期刊
出版社
WILEY
DOI: 10.1002/dad2.12179
关键词
Alzheimer' s disease; biomarkers; mass spectrometry; synaptic pathology
资金
- Eivind and Elsa K. Son Sylvan Foundation
- Herbert and Karin Jacobsson Foundation
- Gun and Bertil Stohne Foundation
- Foundation for Gamla Tjanarinnor
- Felix Neubergh Foundation
- Demensfonden
- Rune and Ulla Almlov Foundation
- Swedish Research Council [2018-02532, 2017-00915]
- European Research Council [681712]
- Swedish State Support for Clinical Research [ALFGBG-720931]
- Alzheimer Drug Discovery Foundation (ADDF), USA [201809-2016862, RDAPB-201809-2016615]
- AD Strategic Fund
- Alzheimer's Association [ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C]
- Foundation of Gamla Tjanarinnor
- Olav Thon Foundation
- Erling-Persson Family Foundation
- Hjarnfonden, Sweden [FO2019-0228, FO2017-0243]
- European Union's Horizon 2020 research and innovation programme under the Marie Skodowska-Curie grant [860197]
- UK Dementia Research Institute at UCL
- Swedish Alzheimer Foundation [AF-742881]
- Swedish government [ALFGBG-715986]
- Swedish County Councils, the ALF-agreement [ALFGBG-715986]
- European Union Joint Program for Neurodegenerative Disorders [JPND2019-466-236]
- Alzheimerfonden [AF-930934]
- Marta and Gustaf Agren Foundation
This study identified a novel panel of synaptic proteins as biomarkers of synaptic dysfunction, with increased concentrations observed in AD patients compared to controls, suggesting their potential use as synaptic biomarkers for AD.
Introduction Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline. Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed. Method Solid-phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17 synaptic proteins in CSF, in two cross-sectional studies including AD (n = 52) and controls (n = 37). Results Increased concentrations of beta-synuclein, gamma-synuclein, neurogranin, phosphatidylethanolamine-binding protein 1, and 14-3-3 proteins were observed in AD patients compared to controls, while neuronal pentraxin-2 and neuronal pentraxin receptor were decreased. Discussion We have established a method with a novel panel of synaptic proteins as biomarkers of synaptic dysfunction. The results indicate that several of the proteins included in the panel may serve as synaptic biomarkers for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据